FLT3 and acute myeloid leukemia: Indeed, highly potent FLT3 inhibitors, such as quizartinib (AC220), have generated substantial antileukemic clinical effects among relapsed/refractory AML patients with FLT3-ITD mutations, as well as a smaller number of patients without a documented FLT3 mutation.